Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery

The past decade has witnessed a paradigm shift in preclinical drug discovery with structure-based drug design (SBDD) making a comeback while high-throughput screening (HTS) methods have continued to generate disappointing results. There is a deficit of information between identified hits and the man...

Descripción completa

Detalles Bibliográficos
Autores principales: Lounnas, Valère, Ritschel, Tina, Kelder, Jan, McGuire, Ross, Bywater, Robert P., Foloppe, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology (RNCSB) Organization 2013
Materias:
Mini Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962124/
https://www.ncbi.nlm.nih.gov/pubmed/24688704
http://dx.doi.org/10.5936/csbj.201302011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962124/
https://www.ncbi.nlm.nih.gov/pubmed/24688704
http://dx.doi.org/10.5936/csbj.201302011

Ejemplares similares